Savara (SVRA) Cash from Financing Activities (2010 - 2026)
Savara (SVRA) posted quarterly Cash from Financing Activities of -$195000.0 for Q1 2026, down 108.41% year-over-year from $2.3 million in Q1 2025, and down 100.14% quarter-over-quarter from $135.6 million in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Cash from Financing Activities for 17 consecutive years, with -$195000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 108.41% year-over-year to -$195000.0; the TTM figure through Mar 2026 stood at $135.3 million (up 12.89% YoY), while the FY2025 annual figure was $137.8 million, up 17.2% from the prior year.
- Cash from Financing Activities slipped to -$195000.0 in Q1 2026 per SVRA's latest filing, from $135.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $135.6 million in Q4 2025 and bottomed at -$843000.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $19.9 million across 5 years, with a median of $49000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 7475600.0% — and 2025, when it plunged 189.09%.
- Savara's Cash from Financing Activities stood at $1000.0 in 2022, then soared by 789400.0% to $7.9 million in 2023, then sank by 110.68% to -$843000.0 in 2024, then surged by 16180.66% to $135.6 million in 2025, then sank by 100.14% to -$195000.0 in 2026.
- Business Quant data shows SVRA's Cash from Financing Activities at -$195000.0 in Q1 2026, $135.6 million in Q4 2025, and -$23000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 189,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 189,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | 135.56 Mn |
| Sep 30, 2025 | -23,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -843,000.00 |
| Sep 30, 2024 | 118.32 Mn |
| Jun 30, 2024 | 55,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 7.90 Mn |
| Sep 30, 2023 | 74.76 Mn |
| Jun 30, 2023 | 104,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 10,000.00 |